Chemokine Therapeutics Withdraws Registration Statement and Implements a Cost Reduction Plan
Vancouver, BC (December 4, 2007) â€“ Chemokine Therapeutics Corp., a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that the Company has withdrawn the registration statement relating to the public offering, announced on May 30, 2007, due to market conditions. The Company is currently evaluating financing alternatives to fund ongoing activities.
The Company has implemented a cost reduction plan that includes reducing the Companyâ€™s workforce by 65% which is expected to yield annual savings of approximately $1,500,000 in direct salaries and related costs. In addition, the remaining management has voluntarily agreed to a 10% reduction in their salaries. This plan is designed to allow the Company to extend its financial resources and focus on essential operational activities for the continued development of its lead product candidates.
As part of the plan, Mr. C. Richard Piazza has resigned as Chief Executive Officer (â€œCEOâ€) of the Company and Mr. Bashir Jaffer, the Companyâ€™s Chief Financial Officer, has been appointed as Interim CEO. Mr. Piazza has accepted a position with another organization; however, he will continue to serve the Company as Chairman of the Board. Dr. Mohammad Azab has also tendered his resignation from the Board of Directors for personal reasons.
The Company would like to thank Mr. Piazza for serving as CEO for the past eight months and Dr. Azab for his services to the Company as a director for the past two years.
About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements such as the Companyâ€™s expected benefits from its cost-saving initiatives and its ability to pursue additional funding alternatives. These forward looking statements involve risks and uncertainties that may cause actual results to differ materially from the forward looking statements made herein. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to ,the Companyâ€™s ability to raise additional funding, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the potential dilutive effects of any future financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.